GLP-1s: 5 Myths, Debunked

By: Mehdia Amini, MD

GLP-1–based medications have transformed the treatment of obesity and metabolic disease. They have also generated an enormous amount of misinformation. As an endocrinologist, I hear the same concerns repeatedly: What about my thyroid? Will my hair fall out? Will this hurt my kidneys? Will I lose muscle and bone? And isn’t taking medication for weight loss basically cheating?

Here are five common GLP-1 myths—and what the evidence actually tells us.

MYTH #1: “I have thyroid disease, so I can’t take a GLP-1.”

FACT: Most thyroid conditions, and even a history of most thyroid cancers, are not contraindications to GLP-1 therapy.

The thyroid warning specifically concerns medullary thyroid carcinoma (MTC), a rare cancer arising from the thyroid’s parafollicular C-cells, and Multiple Endocrine Neoplasia type 2 (MEN2), an inherited syndrome caused by mutations in the RET gene that carries a high risk of developing MTC.

Why the warning? In preclinical studies, GLP-1 receptor agonists caused C-cell hyperplasia and tumors in rodents. However, important biological differences exist between rodent and human thyroid C-cells, and whether these findings translate into an increased risk of MTC in humans remains uncertain. For this reason, a personal or family history of MTC or MEN2 is a contraindication to GLP-1 receptor agonist therapy.

But hypothyroidism, Graves’ disease, and thyroid nodules do not automatically preclude treatment. Neither does a history of most thyroid cancers. Papillary and follicular thyroid cancers arise from thyroid follicular cells, not the C-cells involved in MTC. A history of papillary or follicular thyroid cancer is not, by itself, an FDA-listed contraindication to GLP-1 therapy.

So the important question is not simply, “Have you ever had thyroid cancer?” It is, “What type of thyroid cancer did you have?” The specific thyroid diagnosis matters.

MYTH #2: “GLP-1 medications make your hair fall out.”

FACT: Hair loss has been reported with some GLP-1–based therapies, but the explanation is more complicated than simply blaming the medication.

One potential contributor is telogen effluvium, a temporary form of diffuse hair shedding that can occur after substantial and/or rapid weight loss. It is not unique to GLP-1 therapy - it can also occur after bariatric surgery, significant illness, surgery, and other physiologic stressors.

Nutrition may also play a role. Because these medications reduce appetite and food intake, some patients may inadvertently consume too little protein, iron, zinc, or other nutrients necessary for normal hair growth.

Hair loss has been reported in clinical trials of some GLP-1–based therapies, but it remains unclear how much reflects a direct medication effect versus rapid weight loss, reduced nutritional intake, or other contributing factors.

So hair loss does not automatically mean the medication needs to be stopped. It means we should ask the right questions: How rapidly are you losing weight? Are you eating enough protein and calories? Is there iron deficiency? Is your thyroid function normal? Could something else be contributing?

The goal is not simply weight loss. It is weight loss while maintaining adequate nutrition and overall health.

MYTH #3: “GLP-1 medications damage your kidneys.”

FACT: GLP-1 medications are not considered directly toxic to the kidneys.

There is, however, an important complication to recognize. Significant nausea, vomiting, diarrhea, or markedly reduced food and fluid intake can cause dehydration. In susceptible patients, severe volume depletion can reduce kidney perfusion and precipitate acute kidney injury. That is very different from the medication directly damaging kidney tissue.

In fact, GLP-1 therapy can have important kidney benefits in appropriate patients. In the FLOW trial, which included more than 3,500 patients with type 2 diabetes and chronic kidney disease, semaglutide reduced the risk of the primary composite kidney and cardiovascular outcome by 24%.

So both can be true: dehydration during treatment can precipitate acute kidney injury, while GLP-1 therapy can also provide meaningful kidney protection in appropriately selected patients. The clinical context matters.

MYTH #4: “GLP-1 medications cause muscle and bone loss and increase your risk of fractures.”

FACT: Substantial weight loss can affect both lean mass and bone but this does not mean GLP-therapy directly causes muscle wasting or bone loss.

Let’s start with muscle.
When someone loses a substantial amount of weight, not all of it comes from fat. Some lean mass is typically lost as well. A 2026 meta-analysis found that approximately 25–39% of weight lost with incretin-based therapies was lean mass, depending on the medication. But lean mass is not synonymous with skeletal muscle. DXA-derived lean tissue includes muscle as well as water, organs, connective tissue, and other non-fat tissues. A reduction in measured lean mass therefore should not automatically be labeled “muscle wasting” or sarcopenia.

That does not mean muscle preservation is unimportant. Quite the opposite. The goal should be to maximize fat loss while preserving skeletal muscle, strength, and physical function through adequate protein intake and resistance exercise.

Bone deserves similar attention.
Substantial weight loss can increase bone turnover and reduce bone mineral density, particularly at weight-bearing sites such as the hip. Reduced mechanical loading, nutritional changes, and other physiologic adaptations to weight loss may all contribute. But here is the critical distinction: current evidence does not establish that GLP-1 receptor agonists increase fracture risk. A 2025 meta-analysis of 25 randomized studies found no significant increase in fractures with GLP-1 receptor agonist therapy.

The takeaway should not be “GLP-1s make your bones brittle.” The better message is that substantial weight loss can affect both lean tissue and the skeleton, regardless of how that weight loss is achieved. This deserves particular attention in older adults, postmenopausal women, patients with osteopenia or osteoporosis, and those already at risk for sarcopenia or fracture.

Good obesity care should therefore include adequate protein, resistance and weight-bearing exercise, appropriate calcium and vitamin D intake, adequate overall nutrition, and attention to bone health when clinically indicated. The scale tells us how much weight was lost. It does not tell us what happened to muscle, strength, or skeletal health along the way.

MYTH #5: “Taking a GLP-1 for weight loss is cheating.”

FACT: Obesity is a chronic, biologically complex disease, not a failure of discipline or willpower.

Body weight is regulated by far more than willpower. Appetite, satiety, energy expenditure, genetics, gastrointestinal and adipose-derived hormones, sleep, medications, environment, and reproductive hormones all influence body weight and body composition. Aging and midlife add another layer. Changes in skeletal muscle, energy requirements, sleep, reproductive hormones, and fat distribution can alter body composition. During the menopausal transition, for example, women may experience an increase in visceral adiposity even without dramatic changes in total body weight.

Nutrition and physical activity absolutely matter. They remain foundational components of obesity treatment. But “just eat less and exercise more” is an incomplete description of the physiology of obesity.

We do not tell someone with hypertension that taking blood pressure medication is cheating and they should simply eat less sodium. We do not tell someone with diabetes that medication is cheating, and they should simply exercise harder. Lifestyle matters in those diseases, too. But when medication is medically indicated, we treat the disease. Obesity deserves the same evidence-based approach. Using an appropriately prescribed medication to treat a chronic metabolic disease is not cheating. It is medical treatment.

Key Take Aways

GLP-1–based medications are not miracle drugs. They are not shortcuts, and they are not appropriate for everyone. They are powerful metabolic therapies that can provide substantial health benefits when prescribed thoughtfully to the right patient.

As an endocrinologist, I am not simply asking, “Did the number on the scale go down?” I am asking: Is this medication appropriate? Are we improving metabolic health? Are we maintaining adequate nutrition? Are we preserving muscle, strength, and bone health? Are we managing adverse effects appropriately? And is this treatment sustainable long term?

Because good obesity medicine isn’t about making someone smaller at any cost. It’s about improving health while protecting the rest of the body along the way.

To learn more about if GLP-1s are right for you, schedule with Dr. Mehdia Amini, board certified endocrinologist at Evora Women’s Health.